Regencell Bioscience (RGC) has had the highest return since January 1, 2025 by a small-cap US stock in the Biotechnology Industry, returning 471.1%.
| ASSET | % RETURN |
|---|---|
Regencell Bioscience (RGC) | 471.06% |
Chimerix (CMRX) | 143.3% |
GRAIL, LLC (GRAL) | 108.75% |
Inventiva (IVA) | 77.63% |
AnaptysBio (ANAB) | 54.25% |
Kalvista Pharmaceuticals (KALV) | 51.05% |
Valneva SE ADR (VALN) | 49.57% |
Heron Therapeuti (HRTX) | 47.44% |
Verastem (VSTM) | 46.2% |
Organogenesis (ORGO) | 42.5% |
Sage Therapeutic (SAGE) | 40.61% |
GH Research (GHRS) | 30.55% |
Checkpoint Therapeutics (CKPT) | 28.13% |
Silverback Therapeutics (SPRY) | 27.62% |
Akebia Ther (AKBA) | 25.26% |
Precigen (PGEN) | 25% |
Regenxbio (RGNX) | 16.41% |
Absci (ABSI) | 15.93% |
Rigel Pharmaceuticals (RIGL) | 13.41% |
BioCryst Pharmaceuticals (BCRX) | 10.54% |
Kamada (KMDA) | 9.06% |
MeiraGTx (MGTX) | 8.94% |
Sana Biotechnology (SANA) | 8.59% |
Mineralys Therapeutics, Inc Common Stock (MLYS) | 8.19% |
Kiniksa Pharmaceuticals (KNSA) | 6.83% |
Small-cap stocks are treated as having a market cap between $300M and $2B.
